Measuring Lavender Essential Oil’s Effect on Cancerous Tumors with GC-MS
A recent study aimed to investigate the impact of lavender essential oil (LEO) and of its terpenic components on the properties of glioblastoma (GBM) cells in an in vitro model. The study demonstrated that LEO induces a proliferation slowdown and an impairment of cell migration of GBM cells besides reducing oxidative stress.
SPE-Based Method for Detecting Harmful Textile Residues
January 14th 2025University of Valencia scientists recently developed a method using solid-phase extraction (SPE) followed by high-performance liquid chromatography coupled to high-resolution mass spectrometry (HPLC–HRMS/MS) for detecting microplastics and other harmful substances in textiles.
Investigating Phenolic Content in Walnut Milk Residue with UHPLC–ESI-MS/MS
New research characterizes walnut milk residue according to its phenolic content and antioxidant and cytotoxic potential using ultrahigh-performance liquid chromatography–electrospray tandem mass spectrometry (UHPLC–ESI-MS/MS).
Metabolomics Analysis of Low Birth-Weight Infants Using UHPLC-MS/MS Following Lipid Emulsion
A recent study aimed to directly compare the changes in serum metabolites among very low birth-rate (VLBW) infants following the administration of the soybean oil-based lipid emulsion and soybean oil, medium-chain triglycerides, olive oil, and fish oil (SMOF) lipid emulsion using untargeted metabolomics techniques.
PFAS Analysis in Practice: A RAFA 2024 Interview with Stefan van Leuwen
January 10th 2025At the Recent Advances in Food Analysis (RAFA) conference in 2024, LCGC International sat down with Stefan van Leuwen of Wageningen Food Safety Research to discuss his research, which addresses emerging challenges in circular food production, focusing on the risks posed by pollutants when waste and by-products are repurposed in food systems.
Analyzing New Drug Modalities: An ISC 2024 Interview with Kelly Zhang
January 10th 2025At ISC 2024 in Liverpool, United Kingdom, LCGC International interviewed Kelly Zhang of Genentech about her work analyzing new drug modalities, such as mRNA, oligonucleotides, peptides, and cell and gene therapies.